Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Retained Earnings data on file, last reported at $259.7 million in Q1 2026.

• Quarterly Retained Earnings rose 1256.24% year-over-year to $259.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.7 million (up 1256.24% YoY) and the FY2025 annual result came in at -$13.5 million, up 93.08% from the prior year.
• Retained Earnings advanced to $259.7 million in Q1 2026, from -$13.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $259.7 million in Q1 2026 to a low of -$804.9 million in Q1 2022.
• A 5-year average of -$152.2 million and a median of -$1.0 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 16184.95% — and 2025, when it soared 4217.83%.
• Tracing BMRN's Retained Earnings over 5 years: stood at -$789.2 million in 2022, then soared by 96.35% to -$28.8 million in 2023, then plunged by 576.31% to -$194.7 million in 2024, then jumped by 93.08% to -$13.5 million in 2025, then surged by 2027.8% to $259.7 million in 2026.
• The last three Retained Earnings figures came in at $259.7 million (Q1 2026), -$13.5 million (Q4 2025), and $200.8 million (Q3 2025), per Business Quant data.